


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:






1. (Currently Amended) A compound of formula (I):



(I)

wherein:

R¹ represents a group selected from:



~~each ring of which optionally includes a further heteroatom N,~~

Z represents an optional substituent halogen,

alk represents alkylene or alkenylene,

T represents S, O or NH;

R² represents hydrogen, -C₁₋₆alkyl, -C₁₋₃alkylCONR^aR^b, -C₁₋₃alkylCO₂C₁₋₄alkyl, -CO₂C₁₋₄alkyl or -C₁₋₃alkylCO₂H;

R^a and R^b independently represent hydrogen, -C₁₋₆alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally consisting of an additional heteroatom selected from O, N or S(O)_n, optionally substituted by -C₁₋₄alkyl;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C₁₋₄alkyl, -C₂₋₄alkenyl, -CN, -CF₃, -NR^aR^b, -C₀₋₄alkylOR^e, -C(O)R^f and -C(O)NR^aR^b;

R^e represents hydrogen or -C₁₋₆alkyl;


R^f represents -C₁₋₆alkyl;

Y represents phenyl or a 5- or 6- membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group - C₁₋₂alkylNR^cR^d.

R^c and R^d, together with the nitrogen atom to which they are bonded, form a 4-membered heterocyclic ring optionally substituted by halogen, OH or -OC₁₋₆alkyl, or a 5- or 6- membered non-aromatic heterocyclic ring substituted by OH, -OC₁₋₆alkyl or 1 to 2 halogens, with the proviso that the substituent is not attached to a ring carbon atom adjacent to a heteroatom;

or pharmaceutically acceptable salts or prodrugs derivative thereof.

2. (Currently Amended) A compound according to claim 1 wherein R¹ represents a group selected from:



~~each ring of which optionally includes a further heteroatom N,~~

Z represents an optional substituent halogen,

alk represents alkylene or alkenylene,

T represents S, O or NH;

or pharmaceutically acceptable salts or prodrugs ~~derivative~~ thereof.

3. (Currently Amended) A compound according to claim 1 wherein R² represents hydrogen or pharmaceutically acceptable salts or prodrugs ~~derivative~~ thereof.

4. (Currently Amended) A compound according to claims 1 wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C₁₋₄alkyl or -NR^aR^b or pharmaceutically acceptable salts or prodrugs ~~derivative~~ thereof.

5. (Currently Amended) A compound according to claim 1 wherein Y represents a 5 or 6 membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group -CH₂NR^cR^d or pharmaceutically acceptable salts or prodrugs ~~derivative~~ thereof.

6. (Currently Amended) A compound selected from:

(1*E*)-*N*-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide;

N-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)ethanesulfonamide;

N-((3*S*)-1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-6-chloro-1-benzothiophene-2-sulfonamide;
(*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]ethenesulfonamide;
(1*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide;
6-Chloro-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-benzothiophene-2-sulfonamide; and
6-Chloro-*N*-{1-[2-fluoro-4-(2-{[3-(methyloxy)-1-azetidiny]methyl}-1*H*-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl}-1-benzothiophene-2-sulfonamide formate;
or pharmaceutically acceptable salts or prodrugs derivative thereof.

7. (Cancelled).


8. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt or prodrug derivative thereof together with at least one pharmaceutical carrier or excipient.

9. (Cancelled).

10. (Currently Amended) A method of treating a condition susceptible to amelioration by a Factor Xa inhibitor, wherein said condition is one or more of acute coronary syndromes, prothrombotic sequelae associated with myocardial infarction or heart failure, thromboembolism, acute vessel closure associated with thrombolytic therapy and percutaneous transluminal coronary angioplasty, transient ischemic attacks, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, restenosis, and thromboembolic events associated with atrial fibrillation including stroke, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or prodrug derivative thereof.


11. (Previously Presented) A process for preparing a compound as claimed in claim 1, which comprises:

(a) reacting a compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



OR:

(b) by reacting compounds of formula (I) where R^2 is hydrogen with compounds of formula (XI):



wherein R^2 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkylCONR^aR^b, $-C_{1-3}$ alkylCO₂C₁₋₄alkyl, or $-CO_2C_{1-4}$ alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.